Showing 611-620 of 2293 results for "".
- Fewer Serious Infections Found in MS Patients Treated with Natalizumab Vs Ocrelizumabhttps://practicalneurology.com/news/fewer-serious-infections-found-in-ms-patients-treated-with-natalizumab-vs-ocrelizumab/2470129/A study based on a large insurance claims database found that individuals diagnosed with multiple sclerosis (MS) treated with natali
- Smoking Cessation Helps Improve Outcomes for Black People Living with MShttps://practicalneurology.com/news/smoking-cessation-helps-improve-outcomes-for-black-people-living-with-ms/2470581/Tobacco smoking cessation may improve clinical outcomes for Black people with multiple sclerosis (MS), according to study results presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Compared with Non-Hispanic White people with MS, B
- Large Scale Survey of Patients with MS Uncovers Significant Barriers to Care: 42% of Respondents Do Not See an MS Specialisthttps://practicalneurology.com/news/large-scale-survey-of-ms-patient-needs-uncovers-significant-barriers-to-care-42-do-not-see-an-ms-specialist/2470481/Results from a large-scale, national survey highlight the significant barriers that people living with multiple sclerosis (MS) face in accessing resources and health care in the United States. The top barriers identified from the survey commissioned by The Multiple Sclerosis Association of Americ
- Anaphylaxis Boxed Warning Added to MS Medication Labelhttps://practicalneurology.com/news/anaphylaxis-boxed-warning-added-to-ms-medication-label/2473770/The Food and Drug Administration (FDA) has added a Boxed Warning to the prescribing information of glatiramer acetate, a medication for multiple sclerosis (MS) sold under the brand name Copaxone (glatiramer acetate injection; Teva, Tel Aviv-Yafo, Israel) and the generic name Glatopa (glatiramer a
- McDonald Criteria Updates for MS Diagnosis Announcedhttps://practicalneurology.com/news/mcdonald-criteria-updates-for-ms-diagnosis-announced/2470587/Proposed revisions to the 2017 McDonald diagnostic criteria for multiple sclerosis (MS) were announced at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The updates, which will be published later this year, provide guidance on the use of im
- Neurogenetic Evaluation Identifies Misdiagnosis in Individuals with Atypical MShttps://practicalneurology.com/news/neurogenetic-evaluation-reveals-misdiagnosis-in-individuals-with-atypical-ms/2470585/Increased access to broad-based next generation sequencing could strengthen differential diagnosis in cases of “atypical” multiple sclerosis (MS), according to study results presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTR
- Risk of MS Disability Progression Increases with Autoimmune Comorbiditieshttps://practicalneurology.com/news/risk-of-ms-disability-progression-increases-with-autoimmune-comorbidities/2470468/Study results published in Multiple Sclerosis and Related Disorders showed that multiple sclerosis (MS) patients with certain autoimmune comorbidities are at a higher risk of disability progression. The study examined the effect of concomitant Crohn disease (CD), ulcerative col
- FDA Approves Monoclonal Antibody for Treating Relapsing MShttps://practicalneurology.com/news/fda-approves-monoclonal-antibody-for-treating-relapsing-ms/2470088/The Food and Drug Administration (FDA) approved ublituximab (Briumvi; TG Therapeutics, New York, NY) for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Significant Variance in Outcomes Found in Danish MS Hospitals Rehabilitation Studyhttps://practicalneurology.com/news/significant-variance-in-outcomes-found-in-danish-ms-hospitals-rehabilitation-study/2470205/Results from the Danish MS Hospitals Rehabilitation Study presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) found that multidisciplinary rehabilitation (M
- COVID-19 Patient Registry for People with Autoimmune Diseases, Including MS, Launcheshttps://practicalneurology.com/news/covid-19-patient-registry-for-people-with-autoimmune-diseases-including-ms-launches/2469237/A new longitudinal study Autoimmune COVID-19 Project (NCT04344210) for individuals with multiple sclerosis (MS), arthritis, Crohn’s and colitis, and vasculitis and will track